THE PREMIER BIOPHARMA GATHERING DRIVING BIOPROCESS INNOVATION & MARKET GROWTH ACROSS THE DACH REGION

With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent; a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.  We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognised names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on cell and gene therapies. The company is headquartered in Philadelphia, Pennsylvania, and has more than 730,000 square feet of infrastructure across the United States, Europe, and Asia. Minaris Advanced Therapies has manufactured and released over 7,500 GMP batches on behalf of its clients and supports therapy developers from early-stage development and clinical trials to commercial manufacturing. By combining scientific expertise with best-in-class manufacturing and testing services, the company helps bring safe, effective therapies to patients faster and more efficiently. Visit minaris.com to learn more or download the new company presentation here.

BioProduction by SEKISUI is a microbial fermentation-focused CDMO with over 40 years of expertise in microbial biomanufacturing. We specialize in microbial fermentation, protein purification, and downstream processing for enzymes, recombinant proteins, antibody fragments, and plasmids.

With experience in E. coli, Pichia pastoris, Bacillus, Streptococcus, Streptomyces, fungi, and yeast, we provide seamless process transfer and scale-up to meet diverse biopharmaceutical needs.

Our UK-based facility features fermentation capacities ranging from 2L to 5,000L, advanced chromatography techniques, and lyophilization capabilities. While cGMP capacity expansion for clinical-grade drug substance manufacturing is in progress, we adhere to ISO 9001 standards, ISO 8 cleanroom classifications, and environmental safety regulations, ensuring quality and reliability.

Driven by Kaizen-based continuous improvement and a zero-emissions sustainability commitment, BioProduction by SEKISUI partners with global leaders to deliver scalable, high-quality biomanufacturing solutions. Learn more at bioproduction-sekisui.com.

‍

CELLforCURE by SEQENS, based near Paris, is a leader in the manufacturing of Advanced Therapy Medicinal Products (ATMPs), specialized in both autologous and allogeneic cell and gene therapy solutions. With over a decade of expertise, we provide comprehensive end-to-end services, from Phase I to full-scale commercial production.

Our cutting-edge “one-stop-shop” facility spans 10,000 sqm, including 2,200 sqm of GMP-certified production areas and 7 independent manufacturing lines, each equipped with 8 cleanrooms, ensuring maximum safety and compliance for every product.

As a trusted comprehensive solution provider, we facilitate seamless project development, leveraging in-house Quality Control for 90% of processes to deliver drug products.

With a unique blend of CDMO heritage and proven commercial manufacturing expertise, CELLforCURE is the ideal partner to help bring your innovative therapies to life, transforming groundbreaking ideas into commercial success.

‍

ProBioGen is a premiere, Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines with applying proprietary technologies to improve product quality and features. Combining both state-of-the-art development services, together with intelligent product-specific technologies yields biologics with optimized properties.

ProBioGen has been operational for 30 years. At four locations in Berlin, about 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

Clean Cells is a GMP-certified, FDA-inspected CRO/CMO specializing in biosafety and quality control for biologics, cell and gene therapies, and advanced therapeutics. We support developers from preclinical research to commercial production, offering GMP-compliant biosafety testing, GMP cell and viral bank production, secure storage solutions, and the development of tailored analysis.

Our analytical expertise includes rapid microbiology (qPCR, BactALert), viral safety assays, identity testing (NGS, qPCR), and purity assessment (HCP, residual DNA, etc.). Visit our booth to discuss how we can help accelerate your regulatory success.

ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation biologics and advanced therapies. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio supports its partners in optimizing drug development, accelerating time-to-market, and provides comprehensive life-cycle support.

Through a collaborative and risk-sharing model, ProBio offers flexible options for licensing and co-development of new therapeutics. This enables our partners to effectively navigate the complexities of human disease with adaptable and versatile therapeutic approaches. To learn more about ProBio services, please visit www.probiocdmo.com

‍

Evonik is one of the world leaders in the specialty chemicals industry. Active in more than 100 countries around the world, Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. We contribute small amounts of material that make a big difference. We provide the highest quality cell culture media ingredients for biologic drugs development & manufacturing, produce lipid nanoparticles essential in mRNA-based COVID-19 vaccines, make tires more fuel-efficient, and animal feeds healthier. As one of the key growth regions, Evonik has a strong production and R&D footprint in Asia Pacific. With over 5,000 employees at more than 50 production sites, the region contributed to €3.4 billion sales in 2021.

At Evonik, we offer high-quality cell culture solutions to pharmaceutical and biotech companies to help them boost cell culture performance in the manufacturing of therapeutic proteins like monoclonal antibodies, as well as in the production of viral vectors such as the adeno associated viral (AAV) vectors for gene therapy.

Commercially proven for reliable media performance across countless biological programs, our cQrex® portfolio features a range of peptides and keto acids designed to address key issues in mammalian cell culture.

Our latest offering, plant-derived cholesterol PhytoChol® Biopharma, which has been especially developed for use in animal-free cell culture media formulation, for example in chemically defined media which do not use fetal bovine serum (FBS). In addition, specialty carbohydrates like D-Mannose can be used as alternative energy sources and building blocks for intracellular protein glycosylation, enabling a higher flexibility in the production of therapeutic proteins.

All these cell culture ingredients are non-animal derived, readily available at commercial scale and can be customized to address specific project needs.

BioPharma Asia aims to keep its readers abreast of all developments in Manufacturing, Development, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality articles and webinars written and presented by the most respected authors/presenters, associated with only end-user companies. So, ensuring the information will always be guaranteed to remain timely, informative, and unbiased.